• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Falls Over 200 Points; Adobe Shares Plunge

    3/15/24 2:40:28 PM ET
    $ADBE
    $AVD
    $CDLX
    $CISS
    Computer Software: Prepackaged Software
    Technology
    Agricultural Chemicals
    Industrials
    Get the next $ADBE alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday.

    The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P 500 also fell, dropping, 0.64% to 5,117.35.

    Check This Out: Top 5 Industrials Stocks That May Fall Off A Cliff In Q1

     

    Leading and Lagging Sectors

     

    Materials shares jumped by 0.2% on Friday.

    In trading on Friday, information technology shares fell by 1.4%.

     

    Top Headline

     

    Shares of Adobe Inc. (NASDAQ:ADBE) fell around 14% on Friday after the company issued a weak forecast.

    Adobe reported better-than-expected results for its first quarter but issued weak revenue guidance for the current quarter. The company said it sees second-quarter revenue in the range of $5.25 billion to $5.30 billion versus estimates of $5.31 billion, according to data from Benzinga Pro.

     

    Equities Trading UP

     

    Verb Technology Company, Inc. (NASDAQ:VERB) shares shot up 219% to $0.4461. VERB's MARKET.live launched Facebook and Instagram social shopping technology integration.

    Shares of Cardlytics, Inc. (NASDAQ:CDLX) got a boost, surging 64% to $13.45 after the company reported better-than-expected fourth-quarter earnings.

    American Vanguard Corporation (NYSE:AVD) shares were also up, gaining 22% to $12.91 following fourth-quarter financial results.

     

    Equities Trading DOWN

     

    C3is Inc. (NASDAQ:CISS) shares dropped 62% to $0.0297 after the company announced pricing of a $6 million underwritten public offering.

    Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) were down 29% to $1.1050. SELLAS Life Sciences Group announced a $20 million registered direct offering and concurrent private placement of 13,029316 shares each for combined purchase price of $1.535/share.

    Immuneering Corporation (NASDAQ:IMRX) was down, falling 29% to $2.0450 after multiple analysts downgraded the stock following Thursday data from the company's Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Tech Stocks Delivering High-Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 0.2% to $81.12 while gold traded down 0.3% at $2,162.00.

    Silver traded up 1.5% to $25.435 on Friday, while copper rose 1.9% to $4.1205.

     

    Euro zone

     

    European shares closed mixed today. The eurozone’s STOXX 600 slipped 0.32%, London’s FTSE 100 fell 0.20% while Spain’s IBEX 35 Index rose 1.02% The German DAX fell 0.03% French CAC 40 rose 0.04% while Italy’s FTSE MIB Index gained 0.46%.

    The annual inflation rate in Italy was confirmed at 0.8% in February, while annual inflation rate in France fell to 3% in February from 3.1% a month ago.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Friday, with Japan’s Nikkei 225 falling 0.26%, Hong Kong’s Hang Seng Index falling 1.42%, China’s Shanghai Composite Index gaining 0.54% and India’s S&P BSE Sensex dipping 0.7%.

    China's new home prices fell by 1.4% year-over-year in February, while the People's Bank of China held the interest rate at 2.50%. The unemployment rate for Singapore was confirmed at 2.0% for the fourth quarter.

     

    Economics

     

    U.S. manufacturing production increased by 0.8% month-over-month in February.

    U.S. industrial production rose by 0.1% from the prior month in February.

    The NY Empire State Manufacturing Index fell to -20.9 in March versus -2.4 in February.

    Export prices in the U.S. increased 0.8% month-over-month in February, while import prices rose by 0.3%.

    The University of Michigan consumer sentiment fell to 76.5 in March, recording the lowest reading in three months, compared to 76.9 in February.

    The total number of active U.S. oil rigs climbed by 6 rigs this week, Baker Hughes Inc reported.

    Now Read This: How To Earn $500 A Month From Dollar General Stock Following Earnings Beat

    Get the next $ADBE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADBE
    $AVD
    $CDLX
    $CISS

    CompanyDatePrice TargetRatingAnalyst
    Adobe Inc.
    $ADBE
    2/3/2026$330.00Overweight → Neutral
    Piper Sandler
    Adobe Inc.
    $ADBE
    1/13/2026Outperform → Perform
    Oppenheimer
    Adobe Inc.
    $ADBE
    1/12/2026$290.00Sell
    Goldman
    Adobe Inc.
    $ADBE
    1/9/2026$375.00Outperform → Market Perform
    BMO Capital Markets
    Adobe Inc.
    $ADBE
    1/5/2026$400.00Buy → Hold
    Jefferies
    Adobe Inc.
    $ADBE
    12/15/2025$310.00Sector Weight → Underweight
    KeyBanc Capital Markets
    Adobe Inc.
    $ADBE
    12/15/2025$405.00 → $400.00Outperform
    BMO Capital Markets
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    More analyst ratings

    $ADBE
    $AVD
    $CDLX
    $CISS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adobe downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Adobe from Overweight to Neutral and set a new price target of $330.00

    2/3/26 6:51:31 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Adobe downgraded by Oppenheimer

    Oppenheimer downgraded Adobe from Outperform to Perform

    1/13/26 8:59:51 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Goldman resumed coverage on Adobe with a new price target

    Goldman resumed coverage of Adobe with a rating of Sell and set a new price target of $290.00

    1/12/26 8:11:27 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AVD
    $CDLX
    $CISS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CHIEF LEGAL OFFICER, SECRETARY Bookman Michael

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:44:51 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Business Officer Brakewood Harold Eugene

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:37:55 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Hall Brett Matthew

    4 - Immuneering Corp (0001790340) (Issuer)

    2/5/26 8:32:35 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $AVD
    $CDLX
    $CISS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by C3is Inc.

    SCHEDULE 13G - C3is Inc. (0001951067) (Subject)

    2/11/26 9:57:04 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Adobe Inc.

    SCHEDULE 13G/A - ADOBE INC. (0000796343) (Subject)

    2/5/26 12:23:46 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by C3is Inc.

    SCHEDULE 13D/A - C3is Inc. (0001951067) (Subject)

    2/4/26 5:00:01 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $ADBE
    $AVD
    $CDLX
    $CISS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schall Thomas J. bought $101,041 worth of shares (21,645 units at $4.67), increasing direct ownership by 41% to 74,530 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/20/26 9:17:29 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $10,502 worth of shares (2,298 units at $4.57), increasing direct ownership by 0.61% to 376,496 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/16/26 4:07:43 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $AVD
    $CDLX
    $CISS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAR Technology to Acquire Bridg, Bringing Loyalty and Non‑Loyalty Data Together for Smarter Retail and Restaurant Activation

    Acquisition will accelerate PAR's roadmap for consumer data, loyalty, and media innovation PAR Technology Corporation (NYSE:PAR), a leading global foodservice technology provider, today announced that it has agreed to acquire the identity resolution and shopper intelligence platform Bridg, a division of Cardlytics, Inc. (NASDAQ Global Market: CDLX). The transaction is structured as an acquisition of substantially all Bridg assets. The purchase price is $27.5 million, subject to purchase price adjustments with a maximum total purchase price of $30.0 million, and is payable in shares of PAR Technology common stock. PAR Technology will also assume certain liabilities associated with the acqu

    1/26/26 8:02:00 AM ET
    $CDLX
    $PAR
    Computer Software: Programming Data Processing
    Technology
    Office Equipment/Supplies/Services
    Miscellaneous

    C3is Inc. Provides Fleet Expansion Update in the Tanker Sector and Announces Management's Estimate of Net Asset Value

    ATHENS, Greece, Jan. 23, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, provided today an update on its fleet expansion, with the delivery of two MR product tankers expected between the first quarter and the third quarter of 2026, and announced management's estimate of the Company's Net Asset Value ("NAV") as of September 30, 2025. Fleet Expansion Update Following the delivery of the two MR product tankers scheduled to be delivered between the first quarter and the third quarter of 2026, and assuming no further vessel acquisitions or dispositions, the Company's fleet will consist of s

    1/23/26 8:30:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    C3is Inc. Announces the Acquisition of Two Medium Range Product Tankers

    ATHENS, Greece, Jan. 22, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today the expansion of its fleet by entering into two Memoranda of Agreement for the acquisition of two MR product tankers with an approximate capacity of 50,000 dwt per vessel, both built in South Korea in 2008 and 2011, respectively (the "Transaction" or the "Acquisitions"). The purchase price is $16.88 million for the 2008-built tanker and $22.90 million for the 2011-built tanker. The vessels are expected to be delivered to the Company between the first and third quarters of 2026. Following completion

    1/22/26 4:10:00 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $ADBE
    $AVD
    $CDLX
    $CISS
    Leadership Updates

    Live Leadership Updates

    View All

    Cardlytics Appoints Company Alumnus David Evans as Chief Financial Officer

    Cardlytics Inc. (NASDAQ:CDLX) today announced the appointment of David Evans as its new Chief Financial Officer, effective January 12, 2026. Evans is returning to Cardlytics, having previously held several executive roles including Chief Financial Officer and Chief Administrative Officer. As the returning Chief Financial Officer, Evans will oversee Cardlytics' finance, accounting, and investor relations functions as the company continues to execute against its longer-term growth vision. Evans rejoins Cardlytics after his initial tenure from 2014 to 2020, during which he helped guide the company through its earlier years of growth and a successful IPO in 2018. Evans is a seasoned executive

    12/18/25 8:10:00 AM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Adobe Delivers New AI Innovations, Assistants and Models Across Creative Cloud to Empower Creative Professionals

    Adobe delivers new AI innovations and industry's top AI models across Creative Cloud apps – including Photoshop, Lightroom, Premiere and Illustrator – empowering creative professionals to save time, meet the rising demand for creative content and work with greater power, precision and control. New AI Assistant in Photoshop, powered by agentic AI, enables creative professionals to scale their work and free up time by instructing the assistant to help on a series of repetitive tasks and surface personalized recommendations, all while maintaining creative control. New AI-powered capabilities in Firefly Boards, including image upscaling and prompt generation, empower creative teams to mo

    10/28/25 8:11:00 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $AVD
    $CDLX
    $CISS
    Financials

    Live finance-specific insights

    View All

    C3is Inc. Announces the Acquisition of Two Medium Range Product Tankers

    ATHENS, Greece, Jan. 22, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today the expansion of its fleet by entering into two Memoranda of Agreement for the acquisition of two MR product tankers with an approximate capacity of 50,000 dwt per vessel, both built in South Korea in 2008 and 2011, respectively (the "Transaction" or the "Acquisitions"). The purchase price is $16.88 million for the 2008-built tanker and $22.90 million for the 2011-built tanker. The vessels are expected to be delivered to the Company between the first and third quarters of 2026. Following completion

    1/22/26 4:10:00 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

    NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified Gemcitabine / nab-paclitaxel (mGnP) in first-line pancreatic cancer patients. "We are excited to share updated overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients," said Ben Zeskind, Ph.D

    12/23/25 8:00:00 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $AVD
    $CDLX
    $CISS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verb Technology Company Inc.

    SC 13G/A - Verb Technology Company, Inc. (0001566610) (Subject)

    11/15/24 8:24:57 PM ET
    $VERB
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 4:15:35 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immuneering Corporation

    SC 13G/A - Immuneering Corp (0001790340) (Subject)

    11/14/24 3:03:47 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care